Abstract
Spinal muscular atrophy (SMA) and Lambert Eaton Myasthenic Syndrome (LEMS) are progressive neurologic conditions that manifest as muscular weakness. SMA is hereditary and LEMS is acquired, and LEM is frequently associated with an underlying malignancy such as small cell lung cancer. Both SMA and LEMS patients can develop urinary symptoms as part of the disease progression. SMA can be associated with bothersome nocturia and urinary frequency. Urinary retention has also been reported among LEMS and SMA patients. Urologic treatment goals are supportive and focused on reducing lower urinary tract symptoms and improving bladder emptying, if needed. Both SMA and LEMS patients have high surgical risk due to sensitivity to neuromuscular blocking agents.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Prior TW, Finanger E. Spinal muscular atrophy. GeneReviews. https://www.ncbi.nlm.nih.gov/books/NBK1352/. Accessed on 03 Dec 2018.
Pellizzoni L, Kataoka N, Charroux B, Dreyfuss G. A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell. 1998;95:615.
Wehner KA, Ayala L, Kim Y, Young PJ, Hosler BA, Lorson CL, et al. Survival motor neuron protein in the nucleolus of mammalian neurons. Brain Res. 2002;945(2):160–73.
Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet. 2002;111:477.
Gendron NH, MacKenzie AE. Spinal muscular atrophy: molecular pathophysiology. Curr Opin Neurol. 1999;12(2):137–42.
Panigrahi I, Kesari A, Phadke SR, Mittal B. Clinical and molecular diagnosis of spinal muscular atrophy. Neurol India. 2002;50(2):117–22.
Motomura M, Johnston I, Lang B, et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1995;58:85.
Elmqvist D, Lambert EH. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin Proc. 1968;43:689.
Benatar M, Blaes F, Johnston I, et al. Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line. J Neuroimmunol. 2001;113:153.
Wirtz PW, Bradshaw J, Wintzen AR, Verschuuren JJ. Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families. J Neurol. 2004;251:1255.
Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002;104:359.
Darras BT. Spinal muscular atrophies. Pediatr Clin N Am. 2015;62:743.
Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. 2015;51:157.
Thomas NH, Dubowitz V. The natural history of type I (severe) spinal muscular atrophy. Neuromuscul Disord. 1994;4:497.
Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82:883.
Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33:831.
Clark CV, Newsom-Davis J, Sanders MD. Ocular autonomic nerve function in Lambert-Eaton myasthenic syndrome. Eye (Lond). 1990;4 (. Pt 3:473.
O’Suilleabhain P, Low PA, Lennon VA. Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology. 1998;50:88.
Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2002;73:766.
O’Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988;111(Pt 3):577.
Preston DC, Shapiro BE. Neuromuscular junction disorders. In: Electromyography and neuromuscular disorders: clinical-electrophysiologic correlations. 3rd ed: Elsevier; 2013. p. 529.
Motomura M, Johnston I, Lang B, et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1995;58:85.
Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332:1467.
Oskoui M, Levy G, Garland CJ, et al. The changing natural history of spinal muscular atrophy type 1. Neurology. 2007;69:1931.
Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33:831.
Zerres K, Rudnik-Schöneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52:518.
Kaufmann P, McDermott MP, Darras BT, et al. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology. 2012;79:1889.
Rudnik-Schöneborn S, Hausmanowa-Petrusewicz I, Borkowska J, Zerres K. The predictive value of achieved motor milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III. Eur Neurol. 2001;45:174.
Iannaccone ST. Modern management of spinal muscular atrophy. J Child Neurol. 2007;22(8):974–8. https://doi.org/10.1177/0883073807305670.
Islander G. Anesthesia and spinal muscle atrophy. Paediatr Anaesth. 2013;23(9):804–16. https://doi.org/10.1111/pan.12159. Epub 2013 Apr 19
Graham RJ, Athiraman U, Laubach AE, Sethna NF. Anesthesia and perioperative medical management of children with spinal muscular atrophy. Paediatr Anaesth. 2009;19(11):1054–63. https://doi.org/10.1111/j.1460-9592.2009.03055.x. Epub 2009 Jun 25
Weingarten TN, Araka CN, Mogensen ME. Et. Al. Lambert-Eaton myasthenic syndrome during anesthesia: a report of 37 patients. J Clin Anesth. 2014;26(8):648–53. https://doi.org/10.1016/j.jclinane.2014.09.009. Epub 2014 Nov 18
von Gontard A, Laufersweiler-Plass C, Backes M, Zerres K, Rudnik-Schöneborn S. Enuresis and urinary incontinence in children and adolescents with spinal muscular atrophy. BJU Int. 2001;88(4):409–13.
Querin G, Bertolin C, Da Re E, et al. Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients. J Neurol Neurosurg Psychiatry. 2016;87(8):810–6. https://doi.org/10.1136/jnnp-2015-311305. Epub 2015 Oct 26
Uemura M, Nishimura K, Nakagawa M, et al. A case of Lambert-Eaton myasthnic syndrome associated with small cell lung carcinoma representing as urinary retention. Hinyokika Kiyo. 2003;49(9):535–8.
Satoh K, Motomura M, Suzu H, et al. Neurogenic bladder in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine. J Neurol Sci. 2001;183(1):1–4.
Cameron AP. Medical management of neurogenic bladder with oral therapy. Transl Androl Urol. 2016;5(1):51–62. https://doi.org/10.3978/j.issn.2223-4683.2015.12.07.
Nitti VW, Khullar V, Kerrebroeck P. Et. al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67(7):619–32. https://doi.org/10.1111/ijcp.12194. Epub 2013 May 21
Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018;8(11):e021889. https://doi.org/10.1136/bmjopen-2018-021889.
Wöllner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2016;54(1):78–82. https://doi.org/10.1038/sc.2015.195. Epub 2015 Oct 27
Peyronnet B, Gamé X, Vurture G, Nitti VW, Brucker BM. Botulinum toxin use in Neurourology. Rev Urol. 2018;20(2):84–93. https://doi.org/10.3903/riu0792.
Tullman M, Chartier-Kastler E, Kohan A. Et. al., Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS. Neurology. 2018;91(7):e657–65. https://doi.org/10.1212/WNL.0000000000005991. Epub 2018 Jul 20
Sadiq A, Brucker BM. Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients. Curr Urol Rep. 2015;16(7):44. https://doi.org/10.1007/s11934-015-0519-5.
Vurture G, Peyronnet B, Feigin A. Et. al. outcomes of intradetrusor onabotulinum toxin a injection in patients with Parkinson’s disease. Neurourol Urodyn. 2018;37(8):2669–77. https://doi.org/10.1002/nau.23717. Epub 2018 May 16
Stoffel JT, Peterson AC, Sandhu JS, AM S, Wei JT, Lightner DJ. AUA white paper on nonneurogenic chronic urinary retention: consensus definition, treatment algorithm, and outcome end points. J Urol. 2017;198(1):153–60. https://doi.org/10.1016/j.juro.2017.01.075. Epub 2017 Feb 3
Suzukia Y, Sano N, Shinonaga C, Fukuda M, Hyodo M, Morimoto T. Successful botulinum toxin treatment of dysphagia in a spinal muscular atrophy type 2 patient. Brain and Development. 2007;29(10):662–5. Epub 2007 May 25
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Vurture, G., Peyronnet, B., Brucker, B.M. (2020). Spinal Muscular Atrophy/Lambert Eaton Myasthenic Syndrome. In: Stoffel, J.T., Dray, E.V. (eds) Urological Care for Patients with Progressive Neurological Conditions. Springer, Cham. https://doi.org/10.1007/978-3-030-23277-1_17
Download citation
DOI: https://doi.org/10.1007/978-3-030-23277-1_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-23276-4
Online ISBN: 978-3-030-23277-1
eBook Packages: MedicineMedicine (R0)